Monitor for any subsequent clinical trial announcements or partnership deals leveraging these patent applications, as the IP expansion alone does not move the stock without a clinical or regulatory catalyst.
Price Chart
Executive Summary
Clearmind Medicine announced the U.S. publication of three patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA) for potential therapeutic uses in mental health, pain, and substance use disorders. The patents expand the company's intellectual property portfolio through its ongoing collaboration with NeuroThera Labs Inc. This is a routine IP update with no immediate financial or clinical catalyst.
Key Facts
- Three U.S. patent applications published covering combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA).
- Applications address potential therapeutic uses in depression, PTSD, pain, and substance use disorders.
- Patents result from ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX).
- Clearmind's intellectual property portfolio now consists of 19 patent families and 32 granted patents.
Financial Impact
No financial terms disclosed; patent publications are procedural and do not represent a near-term revenue or cost event.
Risk Factors
- Patent issuance is not guaranteed; pending applications may not result in granted patents.
- No clinical data or regulatory milestones are associated with this announcement.
- Clearmind is a clinical-stage company with no approved products, making it highly dependent on future trial results and financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3367404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers